S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
S&P 500   3,280.35 (+1.13%)
DOW   28,784.21 (+0.87%)
QQQ   221.64 (+1.62%)
AAPL   316.98 (+2.60%)
FB   218.51 (+1.69%)
MSFT   165.31 (+1.87%)
GOOGL   1,453.92 (+1.55%)
AMZN   1,855.00 (+1.46%)
CGC   23.38 (+8.44%)
NVDA   247.76 (+3.15%)
BABA   210.41 (+2.40%)
MU   56.65 (+2.24%)
GE   11.75 (+2.62%)
TSLA   564.12 (+1.09%)
AMD   50.23 (+1.97%)
T   38.60 (+0.89%)
ACB   1.94 (+2.65%)
F   8.96 (+0.79%)
NFLX   351.58 (+2.54%)
PRI   120.87 (+1.50%)
BAC   33.32 (+1.43%)
DIS   138.64 (+2.01%)
GILD   64.60 (+1.21%)
Log in

NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Forecast & News

$12.48
+0.22 (+1.79 %)
(As of 01/28/2020 02:20 PM ET)
Today's Range
$12.40
Now: $12.48
$12.63
50-Day Range
$12.26
MA: $13.92
$15.40
52-Week Range
$9.98
Now: $12.48
$18.23
Volume3,822 shs
Average Volume13,989 shs
Market Capitalization$51.03 million
P/E Ratio8.49
Dividend YieldN/A
Beta0.23
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine. Read More…

Industry, Sector and Symbol

Industry Metal mining
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPNT
CUSIPN/A
Phone310-598-5410

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.98 million
Book Value$4.38 per share

Profitability

Net Income$-21,190,000.00

Miscellaneous

Employees16
Market Cap$51.03 million
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable

Receive OPNT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPNT and its competitors with MarketBeat's FREE daily newsletter.


Opiant Pharmaceuticals (NASDAQ:OPNT) Frequently Asked Questions

What is Opiant Pharmaceuticals' stock symbol?

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

How were Opiant Pharmaceuticals' earnings last quarter?

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) issued its quarterly earnings results on Tuesday, November, 12th. The technology company reported $1.97 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.10 by $1.87. The technology company had revenue of $20.64 million for the quarter, compared to the consensus estimate of $5.73 million. Opiant Pharmaceuticals had a negative return on equity of 7.39% and a net margin of 24.16%. View Opiant Pharmaceuticals' Earnings History.

When is Opiant Pharmaceuticals' next earnings date?

Opiant Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 19th 2020. View Earnings Estimates for Opiant Pharmaceuticals.

What price target have analysts set for OPNT?

1 Wall Street analysts have issued 12-month target prices for Opiant Pharmaceuticals' stock. Their forecasts range from $42.00 to $42.00. On average, they anticipate Opiant Pharmaceuticals' share price to reach $42.00 in the next year. This suggests a possible upside of 236.6% from the stock's current price. View Analyst Price Targets for Opiant Pharmaceuticals.

What is the consensus analysts' recommendation for Opiant Pharmaceuticals?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Opiant Pharmaceuticals.

Has Opiant Pharmaceuticals been receiving favorable news coverage?

Media headlines about OPNT stock have been trending somewhat positive on Tuesday, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news headlines about the technology company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an effect on the stock's share price in the next few days. View News Stories for Opiant Pharmaceuticals.

Are investors shorting Opiant Pharmaceuticals?

Opiant Pharmaceuticals saw a decline in short interest in January. As of January 15th, there was short interest totalling 15,800 shares, a decline of 46.3% from the December 31st total of 29,400 shares. Based on an average daily volume of 18,000 shares, the short-interest ratio is presently 0.9 days. Approximately 0.5% of the company's shares are short sold. View Opiant Pharmaceuticals' Current Options Chain.

Who are some of Opiant Pharmaceuticals' key competitors?

What other stocks do shareholders of Opiant Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Canopy Growth (CGC), Cronos Group (CRON), Vodafone Group (VOD), Synchrony Financial (SYF), Corbus Pharmaceuticals (CRBP), Cyberark Software (CYBR), Sangamo Therapeutics (SGMO) and Xilinx (XLNX).

Who are Opiant Pharmaceuticals' key executives?

Opiant Pharmaceuticals' management team includes the folowing people:
  • Dr. Roger Crystal, CEO & Director (Age 43)
  • Mr. David D. O'Toole, Chief Financial Officer (Age 60)
  • Dr. Phil Skolnick, Chief Scientific Officer (Age 72)
  • Mr. Kevin Andrew Pollack Esq., J.D., M.B.A., Advisor (Age 49)
  • Mr. Quan Vu, VP of Corp. Devel.

Who are Opiant Pharmaceuticals' major shareholders?

Opiant Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Wedge Capital Management L L P NC (0.55%) and TCI Wealth Advisors Inc. (0.08%). Company insiders that own Opiant Pharmaceuticals stock include Ann L Macdougall, David D O'toole, Gabrielle Alison Silver, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas. View Institutional Ownership Trends for Opiant Pharmaceuticals.

Which institutional investors are selling Opiant Pharmaceuticals stock?

OPNT stock was sold by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC. Company insiders that have sold Opiant Pharmaceuticals company stock in the last year include Michael Sinclair, Phil Skolnick and Roger Crystal. View Insider Buying and Selling for Opiant Pharmaceuticals.

Which institutional investors are buying Opiant Pharmaceuticals stock?

OPNT stock was acquired by a variety of institutional investors in the last quarter, including TCI Wealth Advisors Inc.. Company insiders that have bought Opiant Pharmaceuticals stock in the last two years include Ann L Macdougall, David D O'toole and Gabrielle Alison Silver. View Insider Buying and Selling for Opiant Pharmaceuticals.

How do I buy shares of Opiant Pharmaceuticals?

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Opiant Pharmaceuticals' stock price today?

One share of OPNT stock can currently be purchased for approximately $12.48.

How big of a company is Opiant Pharmaceuticals?

Opiant Pharmaceuticals has a market capitalization of $51.03 million and generates $13.98 million in revenue each year. The technology company earns $-21,190,000.00 in net income (profit) each year or ($7.10) on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe.View Additional Information About Opiant Pharmaceuticals.

What is Opiant Pharmaceuticals' official website?

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

How can I contact Opiant Pharmaceuticals?

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]


MarketBeat Community Rating for Opiant Pharmaceuticals (NASDAQ OPNT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  244 (Vote Outperform)
Underperform Votes:  262 (Vote Underperform)
Total Votes:  506
MarketBeat's community ratings are surveys of what our community members think about Opiant Pharmaceuticals and other stocks. Vote "Outperform" if you believe OPNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OPNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel